Montreal Heart Institute

icm-mhi.org

Total trials

100

Active

22

Phase 3

12

Total enrollment

88,974

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 14 of 14 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Colchicine6
Colchicine Placebo2
Aspirin1
Aspirin Placebo1
Prescription of Aspirin1
No prescription1
Ticagrelor + placebo1
Ticagrelor + aspirin1
Combined Epoprostenol Sodium & Milrinone1
Normal saline1
Aspirin 81Mg Ec Tab twice daily for 7 days1
Aspirin 40Mg Chew Tab twice daily for 7 days1
Aspirin 162 mg EC Tab once daily for 7 days1
Aspirin 80 mg EC Tab1

Next readouts

  • 2024-04-01
  • 2026-11-01
  • 2027-05-01
  • 2027-06-01
  • 2027-12
  • 2030-01-01

Top conditions

  • Heart Failure12
  • Coronary Artery Disease9
  • Right Heart Failure5
  • Atrial Fibrillation5
  • Coronary Heart Disease4
  • Right Ventricular Dysfunction4
  • Congestive Heart Failure4
  • Acute Coronary Syndrome4

Frequently asked questions about Montreal Heart Institute

How many clinical trials does Montreal Heart Institute have on ClinicalTrials.gov?
Montreal Heart Institute is listed as the lead sponsor on 100 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
How many of Montreal Heart Institute's trials are in Phase 3?
12 of Montreal Heart Institute's trials are in Phase 3, spread across 14 active drug programs.
What therapeutic areas does Montreal Heart Institute focus on?
Montreal Heart Institute's most-studied conditions on ClinicalTrials.gov are Heart Failure, Coronary Artery Disease, Right Heart Failure, Atrial Fibrillation, Coronary Heart Disease.
When are Montreal Heart Institute's next clinical trial readouts?
Montreal Heart Institute has 6 upcoming primary-completion readouts tracked here; the soonest is “Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes”, expected around 2024-04-01.